Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy
Abstract Background Although IDH-mutant glioma generally has a better prognosis than their IDH-wildtype counterparts, considerable prognostic heterogeneity persists among patients with the same IDH mutation. Current study has primarily focused on the different IDH statuses or grades, while the metab...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14176-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850284749591937024 |
|---|---|
| author | Peng Wang Jiayi Wang Zheng Fang Qiaodong Chen Ying Zhang Xiaoguang Qiu Zhaoshi Bao |
| author_facet | Peng Wang Jiayi Wang Zheng Fang Qiaodong Chen Ying Zhang Xiaoguang Qiu Zhaoshi Bao |
| author_sort | Peng Wang |
| collection | DOAJ |
| description | Abstract Background Although IDH-mutant glioma generally has a better prognosis than their IDH-wildtype counterparts, considerable prognostic heterogeneity persists among patients with the same IDH mutation. Current study has primarily focused on the different IDH statuses or grades, while the metabolic heterogeneity within IDH-mutant gliomas remains insufficiently characterized. This study aims to identify transcriptomic metabolic subtypes and associated immune microenvironment differences to better understand survival variability and potential therapeutic targets in IDH-mutant glioma. Methods Patients with IDH-mutant gliomas were included from four public datasets (TCGA, n = 373; CGGA325, n = 167; CGGA693, n = 333; GLASS, n = 100), supplemented by 22 cases from Beijing Tiantan Hospital as an independent cohort. Consensus clustering was used to define novel metabolic subtypes. Clinical features were assessed using chi-square tests and Kaplan–Meier analysis. Metabolic profiles were characterized through enrichment analysis and GSVA; immune infiltration was analyzed using CIBERSORTx and ESTIMATE. Tumor samples from the independent cohort underwent untargeted metabolomics for validation. LASSO regression was applied to select metabolic signatures, and the CGP2014 drug library was used for drug screening. Results Three metabolic subtypes (C1–C3) with distinct prognoses (p < 0.05) were identified. C1 exhibited enhanced carbohydrate and nucleotide metabolism; C2 displayed upregulated amino acid and lipid metabolism; and C3 demonstrated elevated lipid, nucleotide, and vitamin metabolism. These patterns were validated in the independent cohort. Subtypes were also correlated with immune infiltration. A 13-gene metabolic signature was established to stratify prognostic risk and suggest subtype-specific drug sensitivities. Conclusions Our study provided a novel metabolic subtype for IDH-mutant glioma and highlighted these patients' metabolic heterogeneity and potential therapeutic strategies. |
| format | Article |
| id | doaj-art-35d3a280d1324eb2ace52c7c8af73e96 |
| institution | OA Journals |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-35d3a280d1324eb2ace52c7c8af73e962025-08-20T01:47:29ZengBMCBMC Cancer1471-24072025-04-0125111310.1186/s12885-025-14176-yNovel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapyPeng Wang0Jiayi Wang1Zheng Fang2Qiaodong Chen3Ying Zhang4Xiaoguang Qiu5Zhaoshi Bao6Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical UniversityDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical UniversityDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical UniversityAbstract Background Although IDH-mutant glioma generally has a better prognosis than their IDH-wildtype counterparts, considerable prognostic heterogeneity persists among patients with the same IDH mutation. Current study has primarily focused on the different IDH statuses or grades, while the metabolic heterogeneity within IDH-mutant gliomas remains insufficiently characterized. This study aims to identify transcriptomic metabolic subtypes and associated immune microenvironment differences to better understand survival variability and potential therapeutic targets in IDH-mutant glioma. Methods Patients with IDH-mutant gliomas were included from four public datasets (TCGA, n = 373; CGGA325, n = 167; CGGA693, n = 333; GLASS, n = 100), supplemented by 22 cases from Beijing Tiantan Hospital as an independent cohort. Consensus clustering was used to define novel metabolic subtypes. Clinical features were assessed using chi-square tests and Kaplan–Meier analysis. Metabolic profiles were characterized through enrichment analysis and GSVA; immune infiltration was analyzed using CIBERSORTx and ESTIMATE. Tumor samples from the independent cohort underwent untargeted metabolomics for validation. LASSO regression was applied to select metabolic signatures, and the CGP2014 drug library was used for drug screening. Results Three metabolic subtypes (C1–C3) with distinct prognoses (p < 0.05) were identified. C1 exhibited enhanced carbohydrate and nucleotide metabolism; C2 displayed upregulated amino acid and lipid metabolism; and C3 demonstrated elevated lipid, nucleotide, and vitamin metabolism. These patterns were validated in the independent cohort. Subtypes were also correlated with immune infiltration. A 13-gene metabolic signature was established to stratify prognostic risk and suggest subtype-specific drug sensitivities. Conclusions Our study provided a novel metabolic subtype for IDH-mutant glioma and highlighted these patients' metabolic heterogeneity and potential therapeutic strategies.https://doi.org/10.1186/s12885-025-14176-yGliomaIDH-mutantMetabolismTranscriptomeGene-expression signature |
| spellingShingle | Peng Wang Jiayi Wang Zheng Fang Qiaodong Chen Ying Zhang Xiaoguang Qiu Zhaoshi Bao Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy BMC Cancer Glioma IDH-mutant Metabolism Transcriptome Gene-expression signature |
| title | Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy |
| title_full | Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy |
| title_fullStr | Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy |
| title_full_unstemmed | Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy |
| title_short | Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy |
| title_sort | novel metabolic subtypes in idh mutant gliomas implications for prognosis and therapy |
| topic | Glioma IDH-mutant Metabolism Transcriptome Gene-expression signature |
| url | https://doi.org/10.1186/s12885-025-14176-y |
| work_keys_str_mv | AT pengwang novelmetabolicsubtypesinidhmutantgliomasimplicationsforprognosisandtherapy AT jiayiwang novelmetabolicsubtypesinidhmutantgliomasimplicationsforprognosisandtherapy AT zhengfang novelmetabolicsubtypesinidhmutantgliomasimplicationsforprognosisandtherapy AT qiaodongchen novelmetabolicsubtypesinidhmutantgliomasimplicationsforprognosisandtherapy AT yingzhang novelmetabolicsubtypesinidhmutantgliomasimplicationsforprognosisandtherapy AT xiaoguangqiu novelmetabolicsubtypesinidhmutantgliomasimplicationsforprognosisandtherapy AT zhaoshibao novelmetabolicsubtypesinidhmutantgliomasimplicationsforprognosisandtherapy |